This exploratory correlative study reports a trend toward the absolute risk reduction for neratinib treatment being greater in patients with PIK3CA-altered vs wild-type HER2-positive BC following standard adjuvant chemotherapy and trastuzumab; however, this observation was not statistically significant. This evidence concerns the gene ERBB2 and breast cancer.